Xeris Biopharma Holdings (XERS) EBIT Margin (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly EBIT Margin came in at 9.52% in Q1 2026, up 1466.0% YoY from 0.61% in Q1 2025, and down 51.28% on a QoQ basis from 19.55% in Q4 2025.
Xeris Biopharma Holdings (XERS) EBIT Margin (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of EBIT Margin data on file, last reported at 9.52% in Q1 2026.
- Quarterly EBIT Margin rose 1466.0% year-over-year to 9.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.4% (up 2151.0% YoY) and the FY2025 annual result came in at 8.53%, up 2510.0% from the prior year.
- EBIT Margin fell to 9.52% in Q1 2026, from 19.55% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 19.55% in Q4 2025 to a low of 131.72% in Q1 2022.
- A 5-year average of 27.27% and a median of 22.17% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin surged 21480 bps — and 2024, when it tumbled 1359 bps.
- Tracing XERS's EBIT Margin over 5 years: stood at 45.77% in 2022, then soared by 52 bps to 22.17% in 2023, then jumped by 113 bps to 2.79% in 2024, then jumped by 600 bps to 19.55% in 2025, then plunged by 51 bps to 9.52% in 2026.
- The last three EBIT Margin figures came in at 9.52% (Q1 2026), 19.55% (Q4 2025), and 9.05% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | 5.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.62% |
| Mar 31, 2026 | 9.52% |
| Dec 31, 2025 | 19.55% |
| Sep 30, 2025 | 9.05% |
| Jun 30, 2025 | 6.27% |
| Mar 31, 2025 | -5.14% |
| Dec 31, 2024 | 2.79% |
| Sep 30, 2024 | -23.76% |
| Jun 30, 2024 | -17.03% |
| Mar 31, 2024 | -35.05% |
| Dec 31, 2023 | -22.17% |
| Sep 30, 2023 | -10.17% |
| Jun 30, 2023 | -42.04% |
| Mar 31, 2023 | -40.00% |
| Dec 31, 2022 | -45.77% |
| Sep 30, 2022 | -63.18% |
| Jun 30, 2022 | -74.75% |
| Mar 31, 2022 | -131.72% |
| Dec 31, 2021 | -225.26% |
| Sep 30, 2021 | -220.24% |